中国生物制药:附属公司正大天晴自主研发的国家1类新药TQB6426临床试验申请获FDA批准

智通财经
Sep 03
【中国生物制药:附属公司正大天晴自主研发的国家1类新药TQB6426临床试验申请获FDA批准】中国生物制药公告,附属公司正大天晴自主研发的国家1类新药TQB6426“GPC3抗体药物偶联物”拟用于晚期恶性肿瘤,现已获得美国食品药品监督管理局新药临床试验批准,公司将加速其I期临床试验。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10